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Endometrial pathology in recurrent postmenopausal bleeding – 
observational study of 385 women 
 
Abstract 
Objectives 
Women with recurrent postmenopausal bleeding (PMB) are considered as being at higher risk 
for endometrial hyperplasia and cancer, and guidelines suggest offering hysterectomy in 
unexplained cases with repeated negative investigations. This study aims to determine the 
prevalence of endometrial pathology in women referred with recurrent PMB to help inform 
clinical practice. 
 
Methods 
Observational study, of prospectively collected data over 5-year period, including 1902 
women referred to the PMB clinic. Women were classified into two groups; those with single 
referral episode: 1517 (79.8%), and women with multiple referrals because of recurrent PMB: 
385 (20.2%). 
 
Results 
The prevalence of endometrial hyperplasia or cancer was 32 (8.3%) in women with multiple 
referrals and 159 (10.5%) in those with single referral (p=0.21). The prevalence of benign 
polyps was 80 (20.8%) and 214 (14.1%) in the two groups, respectively (p=0.002). On 
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comparing to single referral, the OR (95% CI) for women with multiple referrals because of 
recurrent PMB to have endometrial polyps was 1.6 (1.2-2.1). 
 
Conclusion 
Women with recurrent PMB had higher prevalence of endometrial polyps, rather than 
hyperplasia or cancer, when compared with those with single referral. Hysteroscopy may be 
warranted as the first line investigation, if PMB recurs, to enable polyp diagnosis. 
 
Keywords  
Endometrial cancer, endometrial hyperplasia, endometrial polyp, recurrent postmenopausal 
bleeding 
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Introduction  
Recurrent postmenopausal bleeding (PMB) is considered as a risk factor for endometrial 
hyperplasia and cancer [1,2], and many gynecologists state: “beware of the weeping womb” 
[3]. The management of these women is inconsistent amongst gynecologists since there is no 
clear pathway or strong evidence to inform clinical practice. The guidelines of the British 
Society of Gynecological Cancer (BCGS) asserts: "In cases of recurrent unexplained PMB 
with repeated negative investigations, hysterectomy may be indicated and should be 
discussed with the patient – Grade D recommendation" [4]. On the other hand, a prospective 
series in the literature documented lower prevalence of endometrial hyperplasia or cancer and 
higher prevalence of endometrial polyps in women with multiple referrals with recurrent 
episodes of PMB (n=106) when compared with those with a single referral episode (n=1430) 
[5]. 
 
PMB is a common condition, affecting 7-15% of postmenopausal women [6], and the 
prevalence of endometrial cancer in these women ranged in various studies from 3% to 10% 
[7]. Most of published data did not discriminate between women with multiple referrals 
because of recurrent PMB and those with a single referral episode. Trans-vaginal ultrasound 
scan (TVS) is the established initial tool of investigation since several studies demonstrated 
its safety [1,8,9] and cost-effectiveness [10]. The prevalence of endometrial cancer is <1% 
when the endometrial thickness (ET) is ≤ 4mm, regular, and no fluid in the uterine cavity 
[11]. It is widely accepted under these circumstances to refrain from further investigations 
[12]. Above this cut-off, endometrial sampling is recommended because the risk of cancer is 
higher [9]. 
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All investigations for PMB carry a false-negative rate for endometrial hyperplasia and cancer 
[2,8,13]. In contrast to the standardized approach to investigating initial episodes of PMB, 
management of recurrent PMB is ambiguous. There is a great deal of diversity amongst 
gynecologists despite it being a common clinical problem with estimated rates for recurrent 
PMB ranging between 4-33% [2,5,14]. Further, there is no clear evidence on when women 
with recurrent PMB should be reinvestigated with some investigators recommending 6-month 
interval [2,8,13], and others suggesting hysteroscopy as the first line investigation tool 
[1,8,13]. 
 
Given the lack of clarity regarding the prevalence of endometrial pathology, the time interval 
for reinvestigation, and the diagnostic algorithm in women with multiple referral episodes 
because of recurrent PMB, this study was conducted to determine the prevalence of 
endometrial hyperplasia, cancer or polyps in these women in comparison with those with a 
single referral episode. The aim was to produce data to help the development of clinical 
practice guidelines about the management work-up. 
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Materials and methods 
The routine demographic and clinical data of the PMB clinic were prospectively collected in 
a specially designed Microsoft Access database, then extracted anonymously and compiled 
on an Excel spreadsheet. The database contained the details of 2005 consecutive women who 
were referred for PMB service at a Sandwell and West Birmingham Hospitals NHS Teaching 
Trust, UK between 1st January 2011 and 31st January 2015. The TVS and histopathology 
reports were accessed using the hospital Electronic Clinical Data Archive System, while 
hysteroscopic (diagnostic or therapeutic) procedure findings were retrieved from the case 
notes. 
 
PMB was defined as an episode of vaginal bleeding occurring ≥ 12 months after cessation of 
menstruation in women aged ≥45 years. Recurrent PMB was defined as bleeding episodes 
that recurred, after negative investigations at first referral, necessitating a new referral to the 
PMB clinic by the family doctor. The recurrence interval is defined as the period between the 
date of referral for the first episode to the date of referral for the subsequent episode as per 
the family doctor’s referral letter. Women with unscheduled bleeding while taking hormone 
replacement therapy (HRT) were also considered to have PMB since all of them in this 
cohort had been on treatment for >6 months [15]. Out of the 2005 women, we excluded (i) 
frail women not fit for investigations (n=10), (ii) women who were referred with incidental 
finding of increased ET without PMB (n=81), and (iii) women diagnosed with hyperplasia at 
the initial visit and managed with progestogen therapy and surveillance being not fit for 
hysterectomy (n=12). The remaining 1902 were included in the analysis. 
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All women attending the PMB clinic underwent pelvic examination and TVS. If the 
endometrium was regular, ≤ 4 mm in thickness, with no evidence of fluid, no further 
investigations were performed. An outpatient Pipelle® endometrial aspiration biopsy was 
performed in women with ET >4 mm, indistinct endometrium or in case of fluid in the cavity 
[9]. For women with first referral episode with PMB, hysteroscopy was performed when the 
sampling device could not be introduced into the uterine cavity, the sample was deemed 
inadequate by the histopathologist, or when focal lesion was seen on TVS [1,5,8,15]. 
However, hysteroscopy was performed in all women with recurrent PMB. All endometrial 
polyps in this series were confirmed on hysteroscopic examination. 
 
Women were classified according to the presenting history into two cohorts: (i) women with 
single referral episode by family doctor with PMB during the study period, and (ii) women 
with multiple referral episodes because of recurrent PMB. We included in this second group 
women who had their first referral episode before or during the study period. Women were 
further categorized according to the investigation results into: (i) group 1 - benign finding 
(including endometrial polyps), and (ii) group 2 - endometrial hyperplasia or cancer. For the 
purposes of this study, endometrial hyperplasia and cancer were combined as a single 
category. This is because of the high rate of concurrent cancer (42.6%) [16,17] and 
progression to cancer (28%) [18] when endometrial atypical hyperplasia is found. 
Endometrial hyperplasia without cytologic atypia was also combined in the same group, 
despite the low progression rate of <5% over 20 years, considering the recent Guidelines of 
the Royal College of Obstetricians and Gynaecologists that recommended at least 
progestogenic therapy and surveillance i.e. these women should not be categorized as having 
negative investigations or benign pathology [15]. 
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Data were collected as part of the routine investigations and treatment, and the project was 
considered as "service evaluation"; therefore, ethics approval was not deemed necessary. 
Service evaluation may not require ethical approval in the UK [19,20]. 
 
Statistical analysis 
Statistical analyses were carried out using IBM® SPSS® Statistics for windows software 
version 20 (International Business Machines corporation, Armonk, NYC, USA). Continuous 
variable indices are presented as mean with standard deviation or as median with inter-
quartile range (IQR) as distribution demands. The difference between groups in last 
menstrual period (LMP) and ET was sought by t test. Age and Body mass index (BMI) were 
not normally distributed; therefore, Mann-Whitney U test was used. Chi-squared test was 
used to test the difference in categorical variables; ethnic origin, hypertension, diabetes and 
HRT use. The strength of association between recurrent PMB and the outcome groups was 
measured by odds ratio (OR) with 95% confidence interval (95% CI). Univariate analysis and 
Multivariate logistic regression analysis (MVLRA) was used for further analysis of the 
recurrent PMB group to identify the predictors of endometrial hyperplasia, cancer and polyps.  
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Results 
The number of women with multiple referrals with recurrent PMB was 385 (20.2%), while 
the number of those with a single referral episode was 1517 (79.8%). The median recurrence 
interval was 24 months (IQR=13-47). Women with multiple referrals because of recurrent 
PMB had significantly older age, longer duration since last menstrual period, higher BMI and 
higher prevalence of hypertension and diabetes. When the investigations revealed benign 
findings, the median (IQR) age of women with recurrent referrals v those with single referral 
was 62 (55-40) v 56 (52-65), p<0.001. However, there was insignificant age difference 
between women in the two groups when the diagnosis of non-atypical hyperplasia (p=0.091) 
or atypical hyperplasia or cancer was made (p=0.76). Women’s demographic and clinical 
characteristics are summarized in table 1. 
 
The total number of women diagnosed with endometrial hyperplasia or cancer was 191 
(10%). The prevalence of endometrial hyperplasia or cancer was 32 (8.3%) in women with 
multiple referrals with recurrent PMB and 159 (10.5%) in those with a single referral episode. 
The difference was statistically insignificant. On comparing to single referral, the OR (95% 
CI) for women with multiple referrals with recurrent PMB to have endometrial hyperplasia or 
cancer was 0.77 (0.5-1.1), p=0.21. On excluding the 186 women with HRT, the result 
remained the same: OR (95% CI) = 0.76 (0.5-1.2), p=0.23. 
 
On further analysis after splitting endometrial non-atypical hyperplasia from atypical 
hyperplasia and cancer, there was no significant difference between women with multiple 
referrals with recurrent PMB and those with single referral episode in the prevalence of 
endometrial non-atypical hyperplasia: OR (95% CI) = 2 (0.8-4.7), p=0.11. Women with 
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multiple referrals were found to have insignificantly lower prevalence of endometrial atypical 
hyperplasia and cancer: OR (95% CI) = 0.64 (0.4-1), p=0.06. 
 
The prevalence of benign endometrial polyps with normal background endometrium was 80 
(20.8%) and 214 (14.1%) in women with multiple referrals and those with a single referral 
episode, respectively. On comparing to single referral, the OR (95% CI) for women with 
multiple referrals because of recurrent PMB to have endometrial polyps was 1.6 (1.2-2.1), 
p=0.002. On excluding the 186 women with HRT, the result remained the same: OR (95% 
CI) = 1.55 (1.15-2.1), p=0.005. 
 
On univariate analysis in women with multiple referrals episodes because of recurrent PMB, 
the median BMI was 30 (IQR=26-36) and 34 (IQR=30-40) in the benign group and in 
hyperplasia and cancer group, respectively (p=0.002). The mean ET was 5.8 mm (SD=5.1) 
and 14.1 mm (SD=7.2) in the benign group and in hyperplasia and cancer group, respectively 
(p<0.001). There was no significant difference in the other demographic and clinical 
variables between the two groups.  
 
On multivariate logistic regression analysis in women with multiple referrals episodes 
because of recurrent PMB, the ET was the only independent predictor for the outcome of 
endometrial hyperplasia and cancer (adjusted OR=1.2, 95% CI = 1.1-.1.3, p<0.001). This 
means that for every 1mm increase in ET, there is a 20% (95% CI=10%-30%) increase in the 
odds of endometrial hyperplasia and cancer, considering the effect of other predictors. 
Neither age, number of years since last menstrual period, hypertension, BMI, diabetes 
independently predicted the outcome of endometrial hyperplasia and cancer.  
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Figure 1 represents a summary for the investigations performed at the first referral for the 385 
women with multiple referrals with recurrent PMB. The recurrence interval is also presented. 
Of them, 42 (11%) women had their first episode investigated before 1st January 2011; the 
date when prospective collection of the PMB clinic data had started. The family doctors’ 
referral letters for the subsequent episodes confirmed previous negative investigations 
although the details are lacking. 
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Discussion 
To our knowledge, this is the largest series with prospectively collected data in the literature 
investigating recurrent PMB. In contrast to the traditional belief, we found that women with 
multiple referrals because of recurrent PMB have less prevalence of endometrial atypical 
hyperplasia and cancer when compared to those with a single referral episode. However; they 
have significantly higher prevalence of benign endometrial polyps similar to two other 
reports in the literature [5,21]. The same result was obtained on excluding HRT users from 
the analysis, which is also similar to previous reports [5,21]. The ET was the only 
independent predictor for endometrial hyperplasia or cancer in these women with 20% rise in 
the risk for every 1mm increase in ET, considering the effect of other predictors. Neither age, 
ethnic origin, BMI, number of years since last menstrual period, hypertension, diabetes or 
HRT use independently predicted the outcome of endometrial hyperplasia and cancer.  
 
Similarly, a prospective study, comparing women with multiple referrals with recurrent PMB 
(n=106) versus those with a single referral episode (n=1832), found that the prevalence of 
endometrial hyperplasia or cancer was significantly less (6.6% v 14.4%, p= 0.04) and the 
prevalence of benign endometrial polyps was significantly higher (28% v 19%, p= 0.02) in 
women with recurrent PMB [5]. Another retrospective study, comparing women with 
multiple referrals with recurrent PMB (n=126) versus those with a single referral episode 
(n=1430), reported no difference in the prevalence of endometrial cancer between the two 
groups over 56 months period [2]. 
 
The prevalence of recurrent PMB varied in published reports between 4-33% [2,14], which 
may reflect the variations in the definition of recurrent PMB. There is no universal definition 
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in the literature, and some studies mixed women who were re-referred with recurrent PMB 
after negative initial investigations with women who suffered multiple episodes of bleeding 
before they got referred for the first time [1]. In our opinion, this is incorrect since women 
who are re-referred with recurrent PMB either have pathology missed during initial 
investigations or have risk factors to develop endometrial pathology. This should not be 
confused with late presentation or late referral which highlights issues around access to care 
rather than underlying risk of pathology. We have been pragmatic and considered as recurrent 
PMB those with multiple referrals after negative initial investigation since this group of 
women is the cause for concern in every day clinical practice. 
 
Little is known about the interval for reinvestigation i.e. the time after which women should 
be reinvestigated if they got re-referred with recurrent PMB after negative initial 
investigations. We found that the median recurrence interval to be 24 months (IQR=13-47). 
No case of endometrial hyperplasia or cancer was diagnosed in the first 10 months after 
negative initial investigations. Similarly, Ronghe and Gaudoin, in a series of 1536 women 
with PMB of whom 126 (8%) had multiple referrals, reported a mean recurrence interval of 
21 months (range: 2–62 months). All the six cases (except one missed at initial hysteroscopy, 
bicornuate uterus) of endometrial atypical hyperplasia or cancer presented with recurrent 
PMB after 6 months (range: 20–57 months) from the negative initial investigations. The 
authors recommended a 6-month interval to reinvestigate women with recurrent PMB [2]. 
Further, two studies from the same center, including 471 women with PMB of whom 47 
(15%) had multiple referrals, reported median recurrence intervals of 49 weeks. The four 
cases of endometrial atypical hyperplasia or cancer presented with recurrent PMB 16-182 
weeks after negative initial investigations. The PMB recurrence rate was not related to 
incorporation of hysteroscopy or polyp removal at the initial work-up [22]. The European 
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Menopause and Andropause Society (EMAS) clinical guidelines suggested that women with 
recurrent or persistent bleeding should be followed up e.g. after 6 months. A combination of 
TVS, hysteroscopy to directly visualize the uterine cavity, and biopsy was advised [23]. 
Similarly, the Scottish Intercollegiate Guidelines Network (SIGN) recommended in year 
2002 that re-investigation of recurrent PMB should be considered after six months of initial 
negative investigations; [9] however, their guidelines on the management of PMB are 
currently under review for updating. 
 
Some investigators suggested that the increase in prevalence of endometrial polyps in women 
with recurrent PMB may reflect the higher accuracy of hysteroscopy for detecting focal 
disease when used at the second presentation i.e. polyps are missed at first presentation when 
TVS is used as the first line investigation [24,25]. Nevertheless, our data suggest that polyps 
de novo may develop more frequently accounting for further bleeding symptoms. The 
prevalence of polyps is highest in the 108 women with recurrent PMB who had polyps 
resected at first presentation as demonstrated in figure 1. Of them, 50 (46.3%) were found to 
have polyps in the subsequent presentations, with median recurrence interval of 27 months 
(IQR=15-52). 
 
The finding that benign endometrial polyps are more prevalent in women with recurrent PMB 
has potential implications for how best to manage these women.  Although the vast majority 
of endometrial polyps are benign [26] and the consequences of diagnosis are deemed less 
serious than endometrial hyperplasia or cancer, they are frequently associated  with abnormal 
uterine bleeding. Removal frequently resolves symptoms, preventing further referrals and 
alleviating women’s anxiety [27]. Our data strongly supports the previous recommendation 
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that all women with recurrent PMB should undergo hysteroscopy as the first line 
investigation since it has high accuracy for enabling diagnosis of focal diseases [5]. The 
Canadian Society of Obstetricians and Gynecologists guidelines states that hysteroscopic 
examination should be considered in women with persistent or recurrent uterine bleeding 
with negative initial investigations irrespective of the menopausal status (II-2B) [28]. 
 
The strength of the present study is that the data were collected prospectively, consecutively, 
and in standardized fashion, minimizing bias from incomplete data. In addition, our findings 
are generalizable given the large sample size, and the fact that we used the widely accepted 
standard protocol in managing women with PMB as highlighted in the methodology.  
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Conclusion 
Women with multiple referrals with recurrent PMB had higher prevalence of endometrial 
polyps, rather than hyperplasia or cancer, when compared with those with a single referral 
episode. Our data support the recommendation that hysteroscopy should be used as the first 
line investigation, if PMB recurs, since it has high sensitivity to enable accurate polyp 
diagnosis. It may be plausible not to re-refer these women for reinvestigations before 6 
months from the negative initial investigations. Polyp resection or morcellation at the initial 
diagnosis may be recommended, and the practice should change to refrain from routinely 
offering hysterectomy to these women. 
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Tables legends  
Figure 1: Summary of the investigations performed and the outcome at first referral for 
women with multiple referral with PMB (n=385) 
Table 1: Women’s demographic and clinical characteristics (n=1902) 
Table 2: Investigation results (n=1902)
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Table 1: Women’s demographic and clinical characteristics (n=1902) 
Variable 
Recurrent PMB 
n=385 (20.2%) 
Single PMB episode 
n=1517 (79.8%) 
Total 
n=1902 
p-Value 
Age     
Group1  62 (55-70) 56 (52-65)  <0.001* 
Group 2 66 (58-71) 63 (57-74)  0.95 
Total 62 (56-70) 56 (52-66)  <0.001* 
LMP 12 (7) 9 (7)  <0.001* 
BMI 30 (26-36) 29 (25-35)  0.027* 
HRT users 38 (9.8%) 148 (9.9%) 186 (9.8%) 0.9 
Hypertension 189 (49.1%) 611 (40.3%) 800 (42.1%) 0.002* 
Diabetes 88 (22.9%) 258 (17.1%) 346 (18.2%) 0.008* 
Endometrial thickness 6.5 (5.8) 6.3 (5.5)  0.32 
Group 1=Benign findings 
Group 2=Endometrial hyperplasia or cancer 
BMI=Body Mass Index 
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CI=Confidence interval 
HRT=Hormone Replacement Therapy 
LMP=Last menstrual period 
*p<0.05 is considered significant 
Values of Age and BMI are expressed as median (inter-quartile range) 
Value of LMP is expressed as mean (standard deviation)  
Values of HRT, hypertension, DM, outcome groups and endometrial polyps are expressed as n (%) 
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Table 1: Investigations results (n= 1902) 
Outcome 
Recurrent PMB 
n=385 (20.2%4) 
Single PMB 
Episode 
n=1517 (79.8%) 
Total 
n=1902 
p value OR (95% CI) 
Group 1 353 (91.7%) 1358 (89.5%) 1711 (90%)   
Endometrial polyp 80 (20.8%) 214 (14.1%) 294 (15.5%) 0.002* 1.6 (1.2-2.1)a 
Other benign findings 273 (70.9%) 1144 (75.2%) 1417 (74.5%)   
Group 2 32 (8.3%) 159 (10.5%) 191 (10%) 0.21 0.77 (0.5-1.1)b 
Group 1=Benign findings 
Group 2=Endometrial hyperplasia or cancer 
CI=Confidence interval 
OR=Odds ratio 
PMB=Postmenopausal bleeding 
Group 1=Benign findings 
Group 2=Endometrial hyperplasia or cancer 
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*p<0.05 is considered significant 
aOR for the likelihood of recurrent PMB to have endometria polyp 
bOR for the likelihood of recurrent PMB to have endometrial hyperplasia and cancer 
 
